The world’s biggest pharmaceutical company, Eli Lilly, has announced a definitive agreement to buy the clinical-stage biopharmaceutical firm AtaiBeckley. The deal is valued at up to $3.8 billion and includes $2.8 billion in upfront cash alongside $1 billion in potential milestone-based payments.
With the Eli Lilly AtaiBeckley acquisition, the company gains immediate access to a cutting-edge psychiatric platform that targets treatment-resistant depression (TRD), a severe form of depression that does not respond to standard therapies, expanding Lilly’s neuroscience pipeline.
Why Eli Lilly Is Buying AtaiBeckley?
The Eli Lilly AtaiBeckley acquisition will provide diversification to the company. While Eli Lilly has recently experienced historic financial success with its diabetes and obesity therapies, the company is actively investing these profits to expand its footprint in various precision medicine therapies.
Eli Lilly’s acquisitions, like Kelonia Therapeutics and 4E Therapeutics, help build a diverse clinical portfolio. With the AtaiBeckley takeover, Lilly gains immediate access to AtaiBeckley’s cutting-edge psychedelics treatments, positioning itself as a leader in innovative neuropsychiatric medicine.
BPL-003: Clinical Core of the Eli Lilly-AtaiBeckley Deal
BPL-003- Nasal Spray
At the center of the Eli Lilly AtaiBeckley acquisition is BPL-003, an intranasal formulation administered as a nasal spray, developed by AtaiBeckley. BPL-003 is an intranasal formulation of a synthetic form of 5-MeO-DMT, a fast-acting psychedelic compound.
BPL-003 is designed specifically for treatment-resistant depression. In Phase 2b trials, BPL-003 demonstrated rapid and durable reductions in depressive symptoms starting just two days after a single, two-hour in-clinic session. The U.S. FDA has already granted BPL-003 Breakthrough Therapy Designation, and Phase 3 preparations have been initiated.
Available Treatments for TRD
Currently, the primary approved treatment option for TRD is Johnson & Johnson’s Spravato, which requires strict, two-hour in-clinic monitoring. However, BPL-003 requires shorter active duration, allowing patients to be discharged in roughly 90 minutes. This makes AtaiBeckley’s BPL-003 highly compatible with existing healthcare infrastructure while drastically reducing clinic complexity.
VLS-01- Buccal Film
The Eli Lilly AtaiBeckley acquisition also includes VLS-01, a DMT-based buccal film (placed inside the cheek) currently in Phase 2b development. Unlike traditional antidepressants that slowly alter chemical neurotransmitter (messenger) levels over weeks, these buccal films work by rapidly restoring the brain’s physical ability to rebuild and strengthen vital neural connections associated with mood regulation.
The Outlook
The Eli Lilly AtaiBeckley acquisition is a watershed moment for pharmaceutical mergers and acquisitions in the mental health sector. Major drugmakers are increasingly entering the psychedelic market, accelerated by policy shifts like the Trump administration’s April 2026 executive order aimed at speeding up psychedelic drug reviews.
The upcoming Phase 3 outcomes and regulatory progress will determine whether these next-generation psychedelic therapies become viable new treatment options for millions of patients suffering from treatment-resistant depression globally.
